Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.53 |
| ▸ | AKT2 | P31751 | 11/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455663 | 0.95 | AKT1 (0.50) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455613 | 0.88 | AKT1 (0.55) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455638 | 0.87 | AKT1 (0.55) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455853 | 0.85 | AKT1 (0.53) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455729 | 0.85 | AKT1 (0.51) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455753 | 0.84 | AKT1 (0.58) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455822 | 0.83 | AKT1 (0.56) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455837 | 0.82 | AKT1 (0.54) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455926 | 0.80 | AKT1 (0.62) | AKT1AKT2AKT3CYP2C9 | |
| Hydrochloric Acid SCHEMBL31455644 | 0.80 | AKT1 (0.62) | AKT1AKT2AKT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |